Published in Lancet Neurol on August 25, 2009
Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy | NCT00159250
RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov (2012) 3.70
In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science (2015) 2.85
A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet (2011) 2.13
Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther (2011) 2.06
Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov (2011) 1.89
miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol Med (2011) 1.80
Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat Rev Genet (2013) 1.70
The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve (2013) 1.63
Muscle histology vs MRI in Duchenne muscular dystrophy. Neurology (2011) 1.53
Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol (2016) 1.53
Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO J (2011) 1.49
Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol Ther (2010) 1.48
Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Mol Ther Nucleic Acids (2012) 1.41
Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res (2010) 1.38
The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy. Mol Ther (2010) 1.38
In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther (2010) 1.33
Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther (2011) 1.32
Preclinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther (2010) 1.32
Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping. Mol Ther (2009) 1.31
Contribution of human muscle-derived cells to skeletal muscle regeneration in dystrophic host mice. PLoS One (2011) 1.31
Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell Mol Life Sci (2009) 1.31
Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol Ther (2011) 1.30
Therapeutic approaches to muscular dystrophy. Hum Mol Genet (2011) 1.30
Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech (2015) 1.30
Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up. J Neurol (2011) 1.28
One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice. Mol Ther (2010) 1.25
Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses (2012) 1.23
Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J Child Neurol (2010) 1.23
Skeletal muscles of ambulant children with Duchenne muscular dystrophy: validation of multicenter study of evaluation with MR imaging and MR spectroscopy. Radiology (2013) 1.22
Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. Mol Ther (2010) 1.20
Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol Ther (2012) 1.18
Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain (2011) 1.17
Therapeutic advances in muscular dystrophy. Ann Neurol (2013) 1.17
A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice. Hum Gene Ther (2013) 1.17
The effects of low levels of dystrophin on mouse muscle function and pathology. PLoS One (2012) 1.16
Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular Dystrophy. PLoS One (2013) 1.16
Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity. Cancer Res (2011) 1.16
Gene therapy for muscular dystrophy: lessons learned and path forward. Neurosci Lett (2012) 1.16
Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. Am J Pathol (2011) 1.15
Gene and cell-mediated therapies for muscular dystrophy. Muscle Nerve (2013) 1.14
Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol Ther (2011) 1.12
Emerging drugs for Duchenne muscular dystrophy. Expert Opin Emerg Drugs (2012) 1.11
Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics (2013) 1.10
Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino. Am J Pathol (2012) 1.10
Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. Mol Ther (2010) 1.10
Expanding the action of duplex RNAs into the nucleus: redirecting alternative splicing. Nucleic Acids Res (2011) 1.10
Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping. Hum Mol Genet (2012) 1.10
Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases. Mol Ther (2014) 1.09
Exon skipping and duchenne muscular dystrophy therapy: selection of the most active U1 snRNA antisense able to induce dystrophin exon 51 skipping. Mol Ther (2010) 1.09
Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy. J Neurol (2012) 1.07
Magnetic resonance imaging and spectroscopy assessment of lower extremity skeletal muscles in boys with Duchenne muscular dystrophy: a multicenter cross sectional study. PLoS One (2014) 1.07
How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse. Hum Mol Genet (2015) 1.07
Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping. Mol Ther (2011) 1.05
Chemical treatment enhances skipping of a mutated exon in the dystrophin gene. Nat Commun (2011) 1.05
Antisense Oligonucleotide (AON)-based Therapy for Leber Congenital Amaurosis Caused by a Frequent Mutation in CEP290. Mol Ther Nucleic Acids (2012) 1.05
Dystrophins, utrophins, and associated scaffolding complexes: role in mammalian brain and implications for therapeutic strategies. J Biomed Biotechnol (2010) 1.04
Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment. Mol Ther (2010) 1.03
Muscle fat-fraction and mapping in Duchenne muscular dystrophy: evaluation of disease distribution and correlation with clinical assessments. Preliminary experience. Skeletal Radiol (2011) 1.02
Mammalian models of Duchenne Muscular Dystrophy: pathological characteristics and therapeutic applications. J Biomed Biotechnol (2011) 1.02
Exon exchange approach to repair Duchenne dystrophin transcripts. PLoS One (2010) 1.02
Assessment of RT-qPCR normalization strategies for accurate quantification of extracellular microRNAs in murine serum. PLoS One (2014) 1.02
Genomics of alternative splicing: evolution, development and pathophysiology. Hum Genet (2014) 1.01
Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice. Mol Ther (2010) 1.01
Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization. PLoS One (2012) 1.00
A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping. PLoS One (2010) 0.98
Drug treatment of Duchenne muscular dystrophy: available evidence and perspectives. Acta Myol (2012) 0.98
Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am J Pathol (2011) 0.98
In vivo MRI characterization of progressive cardiac dysfunction in the mdx mouse model of muscular dystrophy. PLoS One (2012) 0.98
PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Res (2011) 0.97
Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2'OMePS AON and ZM2 NP-AON complexes in mdx mice. J Biomed Biotechnol (2012) 0.97
Progress in gene therapy of dystrophic heart disease. Gene Ther (2012) 0.96
Splicing therapy for neuromuscular disease. Mol Cell Neurosci (2013) 0.95
Silencing human genetic diseases with oligonucleotide-based therapies. Hum Genet (2013) 0.95
Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Ther (2012) 0.95
Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration. Hum Mol Genet (2015) 0.95
Toxicity and efficacy evaluation of multiple targeted polymalic acid conjugates for triple-negative breast cancer treatment. J Drug Target (2013) 0.95
Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer. PLoS One (2012) 0.95
Retracted Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells. J Biol Chem (2012) 0.94
Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice. Sci Rep (2015) 0.94
Evaluation of exon-skipping strategies for Duchenne muscular dystrophy utilizing dystrophin-deficient zebrafish. J Cell Mol Med (2011) 0.93
Spinal muscular atrophy: an update on therapeutic progress. Biochim Biophys Acta (2013) 0.93
Exon 45 skipping through U1-snRNA antisense molecules recovers the Dys-nNOS pathway and muscle differentiation in human DMD myoblasts. Mol Ther (2012) 0.93
Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy. EMBO Mol Med (2015) 0.93
Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient. PLoS One (2010) 0.92
A splice site mutation in laminin-α2 results in a severe muscular dystrophy and growth abnormalities in zebrafish. PLoS One (2012) 0.92
Molecular and cell-based therapies for muscle degenerations: a road under construction. Front Physiol (2014) 0.92
Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. BMC Med Genomics (2011) 0.92
Guidance in social and ethical issues related to clinical, diagnostic care and novel therapies for hereditary neuromuscular rare diseases: "translating" the translational. PLoS Curr (2013) 0.92
Design principles for bifunctional targeted oligonucleotide enhancers of splicing. Nucleic Acids Res (2011) 0.91
Gene therapy for muscular dystrophy: moving the field forward. Pediatr Neurol (2014) 0.91
Dystrophin rescue by trans-splicing: a strategy for DMD genotypes not eligible for exon skipping approaches. Nucleic Acids Res (2013) 0.91
Modulation of RNA splicing as a potential treatment for cancer. Bioeng Bugs (2011) 0.90
Comparative Genomics of X-linked Muscular Dystrophies: The Golden Retriever Model. Curr Genomics (2013) 0.90
Impaired functional communication between the L-type calcium channel and mitochondria contributes to metabolic inhibition in the mdx heart. Proc Natl Acad Sci U S A (2014) 0.89
Targeted skipping of human dystrophin exons in transgenic mouse model systemically for antisense drug development. PLoS One (2011) 0.89
Therapy of Genetic Disorders-Novel Therapies for Duchenne Muscular Dystrophy. Curr Pediatr Rep (2014) 0.89
Engraftment of ES-Derived Myogenic Progenitors in a Severe Mouse Model of Muscular Dystrophy. J Stem Cell Res Ther (2012) 0.89
Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy. Biomed Res Int (2013) 0.88
Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy. Mol Ther (2012) 0.88
Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell (1987) 20.27
Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med (2007) 7.29
Using the Strengths and Difficulties Questionnaire (SDQ) to screen for child psychiatric disorders in a community sample. Br J Psychiatry (2000) 7.18
The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet (1989) 5.09
Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med (2003) 4.03
Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med (2006) 3.74
Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord (2002) 3.52
Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol (2003) 3.46
Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol (2009) 3.01
Validation of the Hospital Anxiety and Depression Scale for use with adolescents. Br J Psychiatry (1999) 2.68
Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat (2009) 2.67
Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. Thorax (1998) 2.50
Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat Biotechnol (2002) 2.38
Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. J Cell Biol (2000) 2.24
Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med (2006) 2.18
Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet (2003) 2.17
Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul Disord (2007) 2.03
Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther (2006) 2.00
Muscle MRI in inherited neuromuscular disorders: past, present, and future. J Magn Reson Imaging (2007) 1.91
Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Genet (1992) 1.81
Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA (2007) 1.78
In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med (2009) 1.66
Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther (2007) 1.63
The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities. J Neurol (1993) 1.37
A short protocol for muscle MRI in children with muscular dystrophies. Eur J Paediatr Neurol (2002) 1.34
Use of epitope libraries to identify exon-specific monoclonal antibodies for characterization of altered dystrophins in muscular dystrophy. Am J Hum Genet (1993) 1.33
Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr Res (2006) 1.22
The use of the social stress and support interview in families with deviant children: methodological issues. Soc Psychiatry (1987) 1.17
Elevation of serum creatine kinase as the only manifestation of an intragenic deletion of the dystrophin gene in three unrelated families. Eur J Paediatr Neurol (1998) 1.06
Application of in vitro Myo-differentiation of non-muscle cells to enhance gene expression and facilitate analysis of muscle proteins. Neuromuscul Disord (1996) 1.03
Muscle MRI findings in a three-generation family affected by Bethlem myopathy. Eur J Paediatr Neurol (2002) 1.02
Computed tomographic patterns of muscles in neuromuscular diseases. Arch Neurol (1984) 1.02
149th ENMC International Workshop and 1st TREAT-NMD Workshop on: "planning phase i/ii clinical trials using systemically delivered antisense oligonucleotides in duchenne muscular dystrophy". Neuromuscul Disord (2008) 0.99
[Family study allows more optimistic prognosis and genetic counselling in a child with a deletion of exons 50-51 of the dystrophin gene]. Arch Pediatr (2007) 0.92
Long-term expression of full-length human dystrophin in transgenic mdx mice expressing internally deleted human dystrophins. Gene Ther (2004) 0.91
A quantitative ELISA for dystrophin. J Immunol Methods (1993) 0.86
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr (2003) 11.88
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol (2011) 9.68
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. Cell (2005) 7.15
Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation (2008) 7.11
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet (2006) 5.85
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J (2014) 5.21
Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature (2002) 5.21
ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J (2011) 5.11
Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov (2013) 4.35
Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med (2006) 3.74
Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord (2002) 3.52
Origin and timing of brain lesions in term infants with neonatal encephalopathy. Lancet (2003) 3.32
Cluster of human tuberculosis caused by Mycobacterium bovis: evidence for person-to-person transmission in the UK. Lancet (2007) 3.31
Titin mutation segregates with hereditary myopathy with early respiratory failure. Brain (2012) 3.02
A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol (2008) 2.95
Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation (2002) 2.89
Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain (2007) 2.88
Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care (2003) 2.82
Dystroglycanopathies: coming into focus. Curr Opin Genet Dev (2011) 2.75
Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther (2008) 2.69
Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan. Hum Mol Genet (2003) 2.69
Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci U S A (2003) 2.65
"Stress" and coronary heart disease: psychosocial risk factors. Med J Aust (2003) 2.63
A mutation in the thyroid hormone receptor alpha gene. N Engl J Med (2011) 2.62
A homozygous mutation in human PRICKLE1 causes an autosomal-recessive progressive myoclonus epilepsy-ataxia syndrome. Am J Hum Genet (2008) 2.58
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med (2005) 2.49
Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol (2003) 2.47
EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography. J Am Soc Echocardiogr (2012) 2.41
Automatic segmentation and reconstruction of the cortex from neonatal MRI. Neuroimage (2007) 2.41
Mutations in SIL1 cause Marinesco-Sjögren syndrome, a cerebellar ataxia with cataract and myopathy. Nat Genet (2005) 2.38
Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain (2009) 2.38
Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat Biotechnol (2002) 2.38
Mutations in HPRP3, a third member of pre-mRNA splicing factor genes, implicated in autosomal dominant retinitis pigmentosa. Hum Mol Genet (2002) 2.34
Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis (2011) 2.32
tRNA splicing endonuclease mutations cause pontocerebellar hypoplasia. Nat Genet (2008) 2.28
Lack of myostatin results in excessive muscle growth but impaired force generation. Proc Natl Acad Sci U S A (2007) 2.25
SOX2 anophthalmia syndrome. Am J Med Genet A (2005) 2.24
Hypothermia and other treatment options for neonatal encephalopathy: an executive summary of the Eunice Kennedy Shriver NICHD workshop. J Pediatr (2011) 2.22
Stress Echocardiography Expert Consensus Statement--Executive Summary: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur Heart J (2008) 2.22
Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur J Echocardiogr (2008) 2.19
Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med (2006) 2.18
Ullrich congenital muscular dystrophy: connective tissue abnormalities in the skin support overlap with Ehlers-Danlos syndromes. Am J Med Genet A (2005) 2.16
Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet (2012) 2.13
Loss-of-function mutations in MICU1 cause a brain and muscle disorder linked to primary alterations in mitochondrial calcium signaling. Nat Genet (2013) 2.11
Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther (2011) 2.06
Cardiac resynchronization therapy: Part 1--issues before device implantation. J Am Coll Cardiol (2005) 2.06
Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry (2012) 2.05
EAE/ASE recommendations for the use of echocardiography in new transcatheter interventions for valvular heart disease. Eur Heart J (2011) 2.04
Mutation in BAG3 causes severe dominant childhood muscular dystrophy. Ann Neurol (2009) 2.03
Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul Disord (2007) 2.03
MRI of moving subjects using multislice snapshot images with volume reconstruction (SVR): application to fetal, neonatal, and adult brain studies. IEEE Trans Med Imaging (2007) 2.03
A population of myogenic stem cells that survives skeletal muscle aging. Stem Cells (2007) 2.03
Echocardiography in aortic diseases: EAE recommendations for clinical practice. Eur J Echocardiogr (2010) 2.01
Cardiac resynchronization therapy: Part 2--issues during and after device implantation and unresolved questions. J Am Coll Cardiol (2005) 1.98
Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements. Cell Mol Life Sci (2012) 1.96
The use of contrast echocardiography for the detection of cardiac shunts. Eur J Echocardiogr (2007) 1.95
Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci U S A (2009) 1.95
Mutations in the gene encoding capillary morphogenesis protein 2 cause juvenile hyaline fibromatosis and infantile systemic hyalinosis. Am J Hum Genet (2003) 1.94
Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. Brain (2013) 1.93
ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome. Nat Genet (2012) 1.93
Muscle MRI in inherited neuromuscular disorders: past, present, and future. J Magn Reson Imaging (2007) 1.91
Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov (2011) 1.89
Tsc1 (hamartin) confers neuroprotection against ischemia by inducing autophagy. Nat Med (2013) 1.89
Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest (2003) 1.89
Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. Cardiovasc Res (2009) 1.82
Muscle magnetic resonance imaging involvement in muscular dystrophies with rigidity of the spine. Ann Neurol (2010) 1.80